Cardiovascular disease (CVD) has consistently been the leading cause of death worldwide. Several clinical and epidemiological studies have demonstrated that an elevated plasma concentration of lipoprotein (a) [Lp(a)] is a causative and independent major risk factor for the development of CVD, as well as calcific aortic valve stenosis. Thus, the therapeutic management of hyperlipoproteinemia (a) has received much attention, as significant reductions in Lp(a) levels may, potentially, favorably affect cardiovascular risk. Aspirin, niacin, estrogens, and statins, which act on different molecular pathways, may be prescribed to patients with mild or modest elevations of Lp(a) levels. Other therapeutic interventions, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, Lp(a) apheresis, and the novel antisense oligonucleotides APO(a)-Rx and APO(a)-LRx, which are being evaluated in ongoing clinical trials, have provided some promising results and can potentially be used in severe cases of hyperlipoproteinemia (a). This review aims to present and discuss the current clinical and scientific data pertaining to the therapeutic options for the management of hyperlipoproteinemia (a).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752750 | PMC |
| http://dx.doi.org/10.7573/dic.212609 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dyslipidemia in Infants: Challenges in Diagnosis and Management.
Tunis Med
December 2024
University El Manar, Faculty of Medecine of Tunis. Pediatrics and Neonatology departement, Yasminette Ben Arous, Tunisia.
Dyslipidemia in infants is a rare condition characterized by abnormal levels of lipids in the blood, such as cholesterol and triglycerides. Early diagnosis poses a challenge due to nonspecific symptoms and lipid criteria differing from adults. Through two clinical cases of familial dyslipidemia (Type 1 Familial Hypercholesterolemia and Type 2b Combined Familial Hyperlipidemia), we highlight the diagnostic and therapeutic challenges encountered in infants, emphasizing the importance of a multidisciplinary approach in care and early screening.
View Article and Find Full Text PDFSYNTAX I score is associated with genetically confirmed familial hypercholesterolemia in chinese patients with coronary heart disease.
BMC Cardiovasc Disord
December 2024
Heart Center & Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, People's Republic of China.
Background: Familial hypercholesterolemia (FH) is a genetically inherited disorder caused by monogenic mutations or polygenic deleterious variants. Patients with FH innate with significantly elevated risks for coronary heart disease (CHD). FH prevalence based on genetic testing in Chinese CHD patients is missing.
View Article and Find Full Text PDFMultifactorial chylomicronemia: keys to detecting severe forms.
Clin Investig Arterioscler
December 2024
Unidad de Lípidos y Riesgo Cardiovascular Servicio de Medicina Interna, Complejo Hospitalario Universitario de A Coruña, A Coruña, España.
Multifactorial chylomicronemia associated with multiple comorbidities, drugs and habits is much more common than familial chylomicronemia, an autosomal recessive disease that can be considered as "rare disease". Like the rest of hypertriglyceridemias, chylomicronemias could be classified as primary or monogenic and secondary in which, on the basis of polygenic predisposition, there is concomitant exposure to multiple triggering factors. In this brief revision, we will review its causes and management as well as the keys to its differential diagnosis of the Multifactorial Chylomicronemia.
View Article and Find Full Text PDFClinical and molecular characterization of familial chylomicronemia in Saudi patients: a retrospective study.
Front Endocrinol (Lausanne)
December 2024
Department of Pediatrics, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Article Synopsis
- - Familial chylomicronemia syndrome (FCS) is a rare but severe form of hypertriglyceridemia, with over 100 cases identified at a specific center aimed at supporting clinicians and enhancing knowledge in disease management.
- - A study of 29 pediatric patients revealed common symptoms such as milky blood samples, family history of hypertriglyceridemia, and acute pancreatitis, with gemfibrozil and fenofibrate proving effective in lowering triglyceride levels.
- - The findings suggest anti-triglyceride medications, particularly fibrates, are safe and effective in managing FCS in kids, with gemfibrozil showing superior results compared to fenofibrate and both drugs causing minimal side effects
Association between the weight-adjusted-waist index and Familial hypercholesterolemia: a cross-sectional study.
BMC Cardiovasc Disord
November 2024
Zhejiang Hospital, Hangzhou, Zhejiang, 310013, China.
Article Synopsis
- This study investigates the weight-adjusted-waist index (WWI) as a new way to measure obesity and its relationship with Familial Hypercholesterolemia (FH).
- Data from 3,698 participants in the NHANES survey revealed that higher WWI is linked to an increased likelihood of FH, with the prevalence rising from 4% in the lowest WWI group to 7.34% in the highest.
- The findings indicate a strong nonlinear correlation between WWI and FH, suggesting new approaches for preventing and treating FH could be developed based on these insights.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!